GHP Investment Advisors Inc. Lowers Stock Holdings in Elevance Health, Inc. $ELV

GHP Investment Advisors Inc. reduced its holdings in Elevance Health, Inc. (NYSE:ELV) by 12.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,351 shares of the company’s stock after selling 1,804 shares during the quarter. GHP Investment Advisors Inc.’s holdings in Elevance Health were worth $3,991,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in ELV. Vermillion & White Wealth Management Group LLC increased its stake in shares of Elevance Health by 94.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock valued at $30,000 after acquiring an additional 37 shares during the last quarter. BOK Financial Private Wealth Inc. purchased a new stake in shares of Elevance Health during the 2nd quarter valued at $32,000. Motco increased its holdings in shares of Elevance Health by 334.8% during the 3rd quarter. Motco now owns 100 shares of the company’s stock worth $32,000 after buying an additional 77 shares during the last quarter. True Wealth Design LLC boosted its holdings in Elevance Health by 431.8% in the third quarter. True Wealth Design LLC now owns 117 shares of the company’s stock valued at $38,000 after acquiring an additional 95 shares during the last quarter. Finally, Glass Jacobson Investment Advisors llc grew its position in Elevance Health by 400.0% during the second quarter. Glass Jacobson Investment Advisors llc now owns 100 shares of the company’s stock valued at $39,000 after acquiring an additional 80 shares during the period. 89.24% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Truist Financial set a $400.00 price objective on Elevance Health in a report on Tuesday, October 14th. Guggenheim increased their target price on shares of Elevance Health from $398.00 to $414.00 and gave the stock a “buy” rating in a research report on Thursday. Sanford C. Bernstein restated an “outperform” rating and issued a $431.00 price target on shares of Elevance Health in a report on Tuesday, January 6th. TD Cowen reaffirmed a “buy” rating on shares of Elevance Health in a research report on Wednesday, November 26th. Finally, Weiss Ratings upgraded shares of Elevance Health from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, January 12th. Twelve investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $399.63.

Elevance Health Trading Down 0.4%

NYSE ELV opened at $370.77 on Friday. The stock has a market cap of $82.40 billion, a P/E ratio of 15.16, a PEG ratio of 1.91 and a beta of 0.51. The company’s fifty day simple moving average is $349.17 and its 200-day simple moving average is $328.79. The company has a current ratio of 1.56, a quick ratio of 1.56 and a debt-to-equity ratio of 0.71. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $458.75.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.